Evidence map›Paper›PMID 38784477›Full record

ArticleRSC medicinal chemistry2024

Exploiting thiol-functionalized benzosiloxaboroles for achieving diverse substitution patterns - synthesis, characterization and biological evaluation of promising antibacterial agents.

Krzysztof Nowicki, Joanna Krajewska, Tomasz M Stępniewski, Monika Wielechowska, Patrycja Wińska, Anna Kaczmarczyk, Julia Korpowska, Jana Selent, Paulina H Marek-Urban, Krzysztof Durka and 3 more

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Krzysztof NowickiFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.ORCID https://orcid.org/0000-0002-6887-5386
Joanna KrajewskaDepartment of Pharmaceutical Microbiology and Bioanalysis, Medical University of Warsaw Banacha 1b 02-097 Warsaw Poland alaudy@wp.pl.ORCID https://orcid.org/0000-0002-4963-9521
Tomasz M StępniewskiGPCR Drug Discovery Lab, Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM) - Department of Medicine and Life Sciences, Pompeu Fabra University (UPF) Carrer del Dr. Aiguader, 88 08003 Barcelona Spain.
Monika WielechowskaFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.
Patrycja WińskaFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.
Anna KaczmarczykFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.
Julia KorpowskaFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.
Jana SelentGPCR Drug Discovery Lab, Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM) - Department of Medicine and Life Sciences, Pompeu Fabra University (UPF) Carrer del Dr. Aiguader, 88 08003 Barcelona Spain.ORCID https://orcid.org/0000-0002-1844-4449
Paulina H Marek-UrbanFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.
Krzysztof DurkaFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.ORCID https://orcid.org/0000-0002-6113-4841
Krzysztof WoźniakFaculty of Chemistry, University of Warsaw Pasteura 1 00-093 Warsaw Poland.ORCID https://orcid.org/0000-0002-0277-294X
Agnieszka E LaudyDepartment of Pharmaceutical Microbiology and Bioanalysis, Medical University of Warsaw Banacha 1b 02-097 Warsaw Poland alaudy@wp.pl.
Sergiusz LulińskiFaculty of Chemistry, Warsaw University of Technology Noakowskiego 3 00-664 Warsaw Poland krzysztof.nowicki2.dokt@pw.edu.pl sergiusz.lulinski@pw.edu.pl.ORCID https://orcid.org/0000-0002-9635-5572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benzosiloxaboroles are an emerging class of medicinal agents possessing promising antimicrobial activity. Herein, the expedient synthesis of two novel thiol-functionalized benzosiloxaboroles 1e and 2e is reported. The presence of the SH group allowed for diverse structural modifications involving the thiol-Michael addition, oxidation, as well as nucleophilic substitution giving rise to a series of 27 new benzosiloxaboroles containing various polar functional groups,

Identifiers

PMID38784477
PMCPMC11110727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.